Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2 diabetes mellitus, show promise in promoting weight loss and improving heart health in obese individuals without diabetes.
How GLP-1 Agonists Might Benefit Cardiovascular Health. GLP-1 agonists have demonstrated a range of cardiovascular benefits, particularly for individuals with obesity, type 2 diabetes, and those at risk of heart disease.
Recent guidelines on obesity and the draft NICE guidance on type 2 diabetes mean that general practice nurses are more likely to be prescribing GLP-1 RAs or helping patients to get the best from their medications so here is some practical advice on how to do so.
Limited data exists about exactly how GLP-1 medications affect fertility, pregnancy and breastfeeding. But as the popularity of these medications grows, so too does the research. As many as a dozen studies involving GLP-1 use are underway for women with PCOS and obesity.
In this Ask Me Anything (AMA) episode, Peter and Bob discuss all things related to GLP-1 agonistsa class of drugs that are gaining popularity for the treatment of obesity. They cover the discovery of these peptides, their physiology, and what it is they do in their natural state.
Studies of GLP-1s show patients average weight loss ranges from 5% to 20% of their body weight. The drugs also show benefits for other health issues such as sleep apnea, cardiovascular disease and arthritis.
GLP-1 RA treatment in Parkinson's Disease.
